Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Innate Pharma is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. These novel drugs consist of monoclonal antibodies that can activate the innate immune system.
Backed by Gilde as an investor, Innate Pharma has advanced its product pipeline to the clinical development stage and built strong commercial partnerships with Novo Nordisk and Bristol-Myers Squibb.
Innate Pharma operates from Marseille, France, and was successfully listed at Euronext Paris (IPH) after its IPO in 2006.
More Innate Pharma news
INNATE PHARMA initiates collaboration with Celgene
Innate Pharma reports positive phase IIa in type C viral hepatitis
INNATE PHARMA Swaps Products with NOVO NORDISK A/S to Obtain full Commercial Rights
Venture&Growth
Ablative Solutions
US-based MedTech focused on treatment of hypertension via renal denervation.
Venture&Growth
Nalu Medical
Nalu Medical is a US medical device company that commercializes alternative proprietary neuromodulation systems. These systems treat chronic neuropathic pain in the back, legs, and other peripheral parts of the body, affecting 1.5 million patients. Nalu’s miniaturized implantable pulse generator
Venture&Growth
Amphista Therapeutics
Amphista Therapeutics is a UK-based company creating first-class therapeutics to selectively degrade and remove disease-causing proteins by harnessing the body’s natural processes. It’s next generation targeted protein degradation TPD-based medicines leverage novel mechanisms that make use of a wider range
